BrainsWay Ltd.BWAYNASDAQ

Overview Intelligence Charts News Fundamentals

Latest News

globenewswire.com

BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

globenewswire.com

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.

BrainsWay continues to activel y evaluat e similar investments in l eading North American m ental h ealth p roviders to raise awareness and e xpand a ccess to transformative care

globenewswire.com

BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care

BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent news issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magnetic stimulation (TMS) for contracted providers whose patients have coverage under Evernorth and Cigna Healthcare® plans. The Evernorth press release stated that the change will be effective on March 6, 2026.

globenewswire.com

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors

defenseworld.net

MariMed (OTCMKTS:MRMD) versus Brainsway (NASDAQ:BWAY) Head-To-Head Review

Brainsway (NASDAQ: BWAY - Get Free Report) and MariMed (OTCMKTS:MRMD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends. Risk and Volatility Brainsway has a beta of 1.2,

globenewswire.com

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™

New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients

globenewswire.com

BrainsWay Announces FDA Approval of Neurolief's Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BrainsWay's strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants BrainsWay's strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants

globenewswire.com

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients

zacks.com

BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens

BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.

defenseworld.net

Brainsway (NASDAQ:BWAY) and Terumo (OTCMKTS:TRUMY) Critical Review

Terumo (OTCMKTS:TRUMY - Get Free Report) and Brainsway (NASDAQ: BWAY - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Profitability This table compares Terumo and Brainsway's net margins, return

globenewswire.com

BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™

Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older

defenseworld.net

Brainsway (NASDAQ:BWAY) vs. Ingen Technologies (OTCMKTS:IGNT) Head to Head Review

Ingen Technologies (OTCMKTS:IGNT - Get Free Report) and Brainsway (NASDAQ: BWAY - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Analyst Ratings This is a summary of current ratings

seekingalpha.com

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

globenewswire.com

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst & Investor Day on Monday, December 1, 2025 at 10:00 AM ET, during which company management will highlight various aspects of BrainsWay's growth strategy. The event will feature Owen Scott Muir, MD, DFAACAP (Co-Founder, Chief Medical Officer, Radial), who will discuss the significant unmet need for various conditions and his clinical experience utilizing Deep TMS™, and Michael Gershenzon, CEO of Stella MSO, a management services organization servicing more than 20 mental health clinics across the U.S. and Israel, who will discuss his experience working with BrainsWay on BrainsWay's strategic minority-stake investment in Stella. To register, click here.

globenewswire.com

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

Multicenter, randomized, controlled study will evaluate Company's next-generation multichannel TMS technology in reducing heavy drinking and cravings Multicenter, randomized, controlled study will evaluate Company's next-generation multichannel TMS technology in reducing heavy drinking and cravings

globenewswire.com

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depression Deep TMS™ becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depression

seekingalpha.com

BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

BrainsWay Ltd. ( BWAY ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Carl Byrnes - Northland Capital Markets, Research Division Raghuram Selvaraju - H.C.